114 related articles for article (PubMed ID: 38537581)
1. Novel hybrid compounds of sclareol and doxorubicin as potential anticancer nanotherapy for glioblastoma.
Stepanović A; Terzić Jovanović N; Korać A; Zlatović M; Nikolić I; Opsenica I; Pešić M
Biomed Pharmacother; 2024 May; 174():116496. PubMed ID: 38537581
[TBL] [Abstract][Full Text] [Related]
2. Novel hybrids of sclareol and 1,2,4-triazolo[1,5-a]pyrimidine show collateral sensitivity in multidrug-resistant glioblastoma cells.
Stojković P; Kostić A; Lupšić E; Jovanović NT; Novaković M; Nedialkov P; Trendafilova A; Pešić M; Opsenica IM
Bioorg Chem; 2023 Sep; 138():106605. PubMed ID: 37201322
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-loaded iron oxide nanoparticles for glioblastoma therapy: a combinational approach for enhanced delivery of nanoparticles.
Norouzi M; Yathindranath V; Thliveris JA; Kopec BM; Siahaan TJ; Miller DW
Sci Rep; 2020 Jul; 10(1):11292. PubMed ID: 32647151
[TBL] [Abstract][Full Text] [Related]
4. Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin.
Senkiv Y; Riabtseva A; Heffeter P; Boiko N; Kowol CR; Jungwith U; Shlyakhtina Y; Garasevych SG; Mitina N; Berger W; Zaichenko A; Stoika R
J Biomed Nanotechnol; 2014 Jul; 10(7):1369-81. PubMed ID: 24804557
[TBL] [Abstract][Full Text] [Related]
5. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
7. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
8. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
10. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
[TBL] [Abstract][Full Text] [Related]
11. A newly synthesized nickel chelate can selectively target and overcome multidrug resistance in cancer through redox imbalance both in vivo and in vitro.
Banerjee K; Biswas MK; Choudhuri SK
J Biol Inorg Chem; 2017 Dec; 22(8):1223-1249. PubMed ID: 29063196
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
13. The role of paclitaxel in the development and treatment of multidrug resistant cancer cell lines.
Podolski-Renić A; Andelković T; Banković J; Tanić N; Ruždijić S; Pešić M
Biomed Pharmacother; 2011 Aug; 65(5):345-53. PubMed ID: 21775090
[TBL] [Abstract][Full Text] [Related]
14. Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells.
Yuan Y; Cai T; Callaghan R; Li Q; Huang Y; Wang B; Huang Q; Du M; Ma Q; Chiba P; Cai Y
Int J Nanomedicine; 2019; 14():2207-2218. PubMed ID: 30988617
[TBL] [Abstract][Full Text] [Related]
15. Glabridin resensitizes p-glycoprotein-overexpressing multidrug-resistant cancer cells to conventional chemotherapeutic agents.
Qian J; Xia M; Liu W; Li L; Yang J; Mei Y; Meng Q; Xie Y
Eur J Pharmacol; 2019 Jun; 852():231-243. PubMed ID: 30959046
[TBL] [Abstract][Full Text] [Related]
16. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.
Shuhendler AJ; Cheung RY; Manias J; Connor A; Rauth AM; Wu XY
Breast Cancer Res Treat; 2010 Jan; 119(2):255-69. PubMed ID: 19221875
[TBL] [Abstract][Full Text] [Related]
17. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
18. Co-loading of photothermal agents and anticancer drugs into porous silicon nanoparticles with enhanced chemo-photothermal therapeutic efficacy to kill multidrug-resistant cancer cells.
Xia B; Zhang Q; Shi J; Li J; Chen Z; Wang B
Colloids Surf B Biointerfaces; 2018 Apr; 164():291-298. PubMed ID: 29413608
[TBL] [Abstract][Full Text] [Related]
19. A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.
Wong HL; Rauth AM; Bendayan R; Manias JL; Ramaswamy M; Liu Z; Erhan SZ; Wu XY
Pharm Res; 2006 Jul; 23(7):1574-85. PubMed ID: 16786442
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of tensin homolog deleted on chromosome ten (PTEN) by ciglitazone sensitizes doxorubicin-resistance leukemia cancer cells to treatment.
Mashayekhi S; Yousefi B; Tohidi E; Darband SG; Mirza-Aghazadeh-Attari M; Sadighparvar S; Kaviani M; Shafiei-Irannejad V; Kafil HS; Karimian A; Jadidi-Niaragh F; Majidinia M
J Cell Biochem; 2019 Sep; 120(9):15719-15729. PubMed ID: 31087712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
